Teresa Young Biography and Net Worth

Executive Vice President, Chief Commercial and Strategy Officer of Seres Therapeutics

Terri Young is the Executive Vice President, Chief Commercial and Strategy Officer at Seres Therapeutics. Prior to joining Seres, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics, where she led development of Sage’s global commercial capabilities, including global marketing, insights and analytics and new product planning. Previously, she held commercial leadership roles of increasing responsibility at Bristol-Myers Squibb, culminating in her role as Vice President and General Manager, Cardiovascular, in which she led the global ELIQUIS® business to become the company’s largest product by revenue. Earlier in her career, Dr. Young held marketing and sales roles at GlaxoSmithKline, where she catalyzed growth for the company’s Urology, Diabetes and NeuroHealth organizations. Dr. Young received her B.S. in pharmacy and her Ph.D. in healthcare marketing from the University of South Carolina. Dr. Young is a member of the Women in Bio and Healthcare Businesswomen’s Association, and served on the Advisory Board of the Healthcare Businesswomen’s Association.

What is Teresa L. Young's net worth?: The estimated net worth of Teresa L. Young is at least $27,864.04 as of August 5th, 2024. Dr. Young owns 3,908 shares of Seres Therapeutics stock worth more than $27,864 as of June 4th. This net worth estimate does not reflect any other investments that Dr. Young may own. Additionally, Dr. Young receives an annual salary of $606,330.00 as Executive Vice President, Chief Commercial and Strategy Officer at Seres Therapeutics. Learn More about Teresa L. Young's net worth.
How old is Teresa L. Young?: Dr. Young is currently 57 years old. There are 5 older executives and no younger executives at Seres Therapeutics. The oldest executive at Seres Therapeutics is Mr. Thomas J. DesRosier Esq., J.D., Chief Legal Officer, Executive VP & Secretary, who is 69 years old. Learn More on Teresa L. Young's age.
What is Teresa L. Young's salary?: As the Executive Vice President, Chief Commercial and Strategy Officer of Seres Therapeutics, Inc., Dr. Young earns $606,330.00 per year. There are 4 executives that earn more than Dr. Young. The highest earning executive at Seres Therapeutics is Mr. Eric D. Shaff M.B.A., President, CEO & Director, who commands a salary of $1,020,000.00 per year. Learn More on Teresa L. Young's salary.
How do I contact Teresa L. Young?: The corporate mailing address for Dr. Young and other Seres Therapeutics executives is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. Seres Therapeutics can also be reached via phone at (617) 945-9626 and via email at ctanzi@serestherapeutics.com. Learn More on Teresa L. Young's contact information.
Has Teresa L. Young been buying or selling shares of Seres Therapeutics?: Teresa L. Young has not been actively trading shares of Seres Therapeutics during the last ninety days. Most recently, Teresa L. Young sold 1,224 shares of the business's stock in a transaction on Monday, August 5th. The shares were sold at an average price of $21.60, for a transaction totalling $26,438.40. Following the completion of the sale, the insider now directly owns 3,908 shares of the company's stock, valued at $84,412.80. Learn More on Teresa L. Young's trading history.
Who are Seres Therapeutics' active insiders?: Seres Therapeutics' insider roster includes Thomas DesRosier (EVP), Matthew Henn (Insider), Eric Shaff (https://ir.pragroup.com/board-of-directors?item=14), and Teresa Young (Executive Vice President, Chief Commercial and Strategy Officer). Learn More on Seres Therapeutics' active insiders.
Are insiders buying or selling shares of Seres Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 13 times. They sold a total of 3,569 shares worth more than $61,314.60. The most recent insider tranaction occured on February, 18th when insider Matthew R Henn sold 197 shares worth more than $3,191.40. Insiders at Seres Therapeutics own 4.7% of the company. Learn More about insider trades at Seres Therapeutics.
Information on this page was last updated on 2/18/2025.

Teresa L. Young Insider Trading History at Seres Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/5/2024	Sell	1,224	$21.60	$26,438.40	3,908
2/16/2024	Sell	168	$21.60	$3,628.80	785

Teresa L. Young Buying and Selling Activity at Seres Therapeutics

Seres Therapeutics Company Overview

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $7.13

$6.96

$7.19

50 Day Range

MA: $9.11

$6.77

$14.00

2 Week Range

Now: $7.13

$6.53

$30.60

Volume

62,725 shs

Average Volume

145,897 shs

Market Capitalization

$62.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.89

Teresa Young Biography and Net Worth

What is Teresa L. Young's net worth?

How old is Teresa L. Young?

What is Teresa L. Young's salary?

How do I contact Teresa L. Young?

Has Teresa L. Young been buying or selling shares of Seres Therapeutics?

Who are Seres Therapeutics' active insiders?

Are insiders buying or selling shares of Seres Therapeutics?